Generics - Oncology, Rest of the World


Current filters:

OncologyRest of the World

Popular Filters

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal


The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

Hikma signs deal with GP Pharma for Lutrate 1 month in MENA region


Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) has signed a license and supply agreement for the…

GenericsGP PharmHikma PharmaceuticalsLicensingLutrateOncologyRest of the World

AEterna Zentaris signs up Hikma to commercialize perifosine in MENA region


Canada’s AEterna Zentaris (TSX: AEZ) has signed an exclusive commercialization and licensing agreement…

AEterna ZentarisGenericsHikma PharmaceuticalsLicensingOncologyperifosinePharmaceuticalRest of the World

Back to top